Bayer CropScience (506285) Q4 2005 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2005 earnings summary
19 Oct, 2026Executive summary
FY05 sales and other operating income reached Rs 7,664.60m; profit after tax rose 41% YoY to Rs 371.47m.
Crop protection market share increased to 16% despite a 12% industry decline, adverse weather effects, Bt cotton adoption and generic-led price erosion.
Consolidated PAT was Rs 383.47m versus Rs 314.53m; prior-year business disposals limit comparability.
Financial highlights
Standalone sales and other operating income were Rs 7,664.60m versus Rs 7,563.56m; other income rose to Rs 391.38m from Rs 261.72m.
Standalone PBT before prior-period and exceptional items was Rs 815.97m versus Rs 513.27m; reported PBT was Rs 746.84m after net items of Rs 69.13m.
Standalone PAT was Rs 371.47m versus Rs 263.61m; consolidated PAT was Rs 383.47m versus Rs 314.53m.
Consolidated sales and other operating income were Rs 7,750.93m versus Rs 8,430.84m; the subsidiary’s previous-year business sales make the comparison less meaningful.
Exports rose to Rs 867.76m from Rs 688.17m; export turnover in the segment disclosure was Rs 921.38m versus Rs 688.17m.
Outlook and guidance
Crop protection market recovery depends on normal monsoon timing and distribution, commodity prices and the impact of genetically modified crops.
Three new crop-protection product registrations were expected in 2006, with potential to add revenue through new crop-pest segments.
Two Environmental Science launches were planned for 2006 to strengthen Vector Control and Professional Pest Control positions.
Latest events from Bayer CropScience
- CropScience scale expanded through merger, while one-offs weighed on reported earnings.506285
Q4 2003 - Drought drove a sharp earnings decline, while export and specialty-business growth offered offsets.506285
Q4 2002 - PBT improved, but adjusted earnings faced portfolio, monsoon and pricing headwinds.506285
Q4 2004 - Profit rose as new products and seed distribution broadened growth plans; Thane closures triggered impairment.506285
Q4 2006 - 15-month PAT was Rs 491m; Thane restructuring costs offset investment-sale gains.506285
Q4 07/08 - PAT reached Rs. 944.59 million as new products met rising crop-protection demand.506285
Q4 08/09 - Sales and PAT rose as new launches supported growth amid pricing and operational risks.506285
Q4 09/10 - Revenue advanced and PAT grew modestly as innovation-led expansion met pricing and regulatory risks.506285
Q4 10/11 - Revenue and PAT rose despite a ₹579m Thane remediation charge.506285
Q4 11/12